1-20 of 325
myalgia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment Patterns and Outcomes of 1205 Patients on Novel Agents in the US Veterans Health Administration (VHA) System: Results from the Largest Retrospective EMR and Chart Review Study in the Real-World Setting

Free
Christopher R Frei, Hannah Le, PharmD, MPH, Daniel McHugh, Cynthia Elesinmogun, PharmD, Samantha Galley, Kathleen Franklin, Juan Tavera, Michelle Janania Martinez, MD, David J Gregorio, DO, Snegha Ananth, MBBS, Ricardo Uribe, Prathibha Surapaneni, Manuel Ricardo Espinoza-Gutarra, MD, Michael Song, Xavier Jones, Chengwen Teng, Obiageri O Obodozie-Ofoegbu, Zohra Nooruddin, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 795.
https://doi.org/10.1182/blood-2019-122434
Published: 2019
Journal Articles

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Free
Andrew Kent, MD PhD, Sumithira Vasu, MDMBBS, Derek Schatz, Natalie Monson, Steven Devine, MD, Clayton Smith, MD, Jonathan A Gutman, MD, Daniel A Pollyea, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1311.
https://doi.org/10.1182/blood-2019-127418
Published: 2019
Journal Articles

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Free
Paolo Strati, MD, Ralph J. Johnson, PhD, Sheryl G Forbes, Loretta J. Nastoupil, MD MSc, Felipe Samaniego, MD, Eric Davis, MD, Michael R Green, PhD, Luis Fayad, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Michael L. Wang, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1533.
https://doi.org/10.1182/blood-2019-129311
Published: 2019
Journal Articles

Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)

Free
Veronica A Guerra, MD, Jan A. Burger, MD PhD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 567.
https://doi.org/10.1182/blood-2019-125970
Published: 2019
Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Free
Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 674.
https://doi.org/10.1182/blood-2019-124360
Published: 2019
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Free
Ruben A Mesa, MD, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Carrie Brownstein, MD, Shien Guo, PhD, Xiaomei Ye, MS, Claire N Harrison, Professor
Journal: Blood
Blood (2019) 134 (Supplement_1): 704.
https://doi.org/10.1182/blood-2019-129020
Published: 2019
Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Free
Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2325.
https://doi.org/10.1182/blood-2019-124176
Published: 2019
Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Free
David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Naranie Shanmuganathan, MBBS FRACP FRCPA, Andrew Grigg, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, FRACP,FRCPA,PhD, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, David M Ross, MD PhD, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, MBBS FRACP FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP FRCPA, Nicholas Viiala, MBBS FRACP FRCPA, Robert Weinkove, MD, Agnes S. M. Yong, MD PhD, Deborah L. White, PhD FFSc (RCPA), Susan Branford, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2019) 134 (Supplement_1): 2926.
https://doi.org/10.1182/blood-2019-125740
Published: 2019
Journal Articles

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Free
Christopher Pleyer, MD, Jeffrey Cohen, MD, Susan Soto, Mir Ali, PhD, Inhye E Ahn, MD, Pia Nierman, BSN, MA, RN, Janet Valdez, Jennifer Lotter, PA-C, Jeanine Superata, RN, Xin Tian, Adrian Wiestner, MD PhD, Clare Sun, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3053.
https://doi.org/10.1182/blood-2019-121675
Published: 2019
Journal Articles

Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029

Free
Zhitao Ying, MD PhD, Pengpeng Xu, MD, Li Wang, MD PhD, Shu Cheng, MD PhD, Wen Wu, MD PhD, Wen Wang, MD PhD, Ming Hao, PhD, Su Yang, Harry Lam, PhD, James Li, Hongxia Zheng, MD PhD, Weili Zhao, MD PhD, Yuqin Song, MD PhD, Jun Zhu, BS
Journal: Blood
Blood (2019) 134 (Supplement_1): 2876.
https://doi.org/10.1182/blood-2019-127751
Published: 2019
Journal Articles

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Free
Jorge E. Cortes, MD, Dong-Wook Kim, Franck E Nicolini, MD PhD, Tapan Saikia, MD, Aude Charbonnier, Jane F. Apperley, MD FRCP, FRCPath, MB, Krishna Rathnam, Michael W. Deininger, Hugues De Lavallade, Navin Khattry, MD DM MDcal Oncology, Andrew Whiteley, MD, Michael J. Mauro, MD, Gregor Verhoef, MD PhD, Carlo Gambacorti-Passerini, MD, Alessandro Lucchesi, MD, Shashikant Apte, MD FRCPA, Granacher Nikki, Siu-Long Yao, MD, Mudgal Kothekar, MD, Jayasree Sreenivasan, Msc, Bimba HV, MD, Geetanjali Chimote, MBBS, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4158.
https://doi.org/10.1182/blood-2019-129751
Published: 2019
Journal Articles

Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome

Free
Kelly S. Chien, MD, Mahesh Swaminathan, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Nicholas J. Short, MD, Kelly Soltysiak, PhD, Sherry A. Pierce, BSN, BA, Jane Waukau, BSN, RN, Darla Miller, Jorge E. Cortes, MD, Yesid Alvarado, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4252.
https://doi.org/10.1182/blood-2019-129226
Published: 2019
Journal Articles

Real-World Outcomes for 205 Danish Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Free
Kathrine Aarup, Lisbeth Enggaard, MD, Robert Schou Pedersen, MD PhD, Rasmus Heje Thomsen, Olav Jonas Bergmann, Mikael Frederiksen, Ilse Christiansen, Tine Nielsen, Henrik Frederiksen, MD Prof, Carsten Utoft Niemann, MD PhD Ass. Prof, Michael Asger Andersen, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1767.
https://doi.org/10.1182/blood-2019-123011
Published: 2019
Journal Articles

Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors

Free
Roberto Latagliata, Imma Attolico, MD, Malgorzata Monika Trawinska, MD, Isabella Capodanno, MD, Mario Annunziata, MD, Chiara Elena, MD, Luigiana Luciano, Monica Crugnola, MD, Micaela Bergamaschi, MD, Massimiliano Bonifacio, MD, Claudia Baratè, Endri Mauro, MD, Gianni Binotto, MD, Nicola Sgherza, MD, Chiara Aguzzi, MD, Barbara Monteleone, MD, Federica Sorà, MD, Giovanni Caocci, MD, Debora Luzi, Elena Mariggiò, MD, Luigi Scaffidi, MD, Daniele Cattaneo, MD, Antonella Gozzini, MD, Ambra Di veroli, Sara Galimberti, MD PhD, Alessandra Iurlo, MD PhD, Massimo Breccia, MD, Giorgina Specchia, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1649.
https://doi.org/10.1182/blood-2019-127029
Published: 2019
Journal Articles

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Free
Katia B Pagnano, MD PhD, Fernanda S Seguro, MD, Eliana C Miranda, PhD, Ana Beatriz Pascoal Lopes, Andre Abdo, MD, Marcia Torresan Delamain, MD, Thales Pereira, MD, Gislaine Borba Duarte, MD, Fernanda Maria Santos, Jessica CN Vianna, Matheus Sebastian Da Silva, Luciana Nardinelli, M.Sc, Valquiria Povoa, Graziele Pavan, Bruna R Vergilio, Vanderson Rocha, MD PhD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Israel Bendit, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1655.
https://doi.org/10.1182/blood-2019-125368
Published: 2019
Journal Articles

Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma

Free
Francis K. Buadi, MB, CHB, Martha Q. Lacy, MD, Angela Dispenzieri, MD, Gabriela Perez, MS, Morie A. Gertz, MD, Prashant Kapoor, MD, Suzanne R. Hayman, MD, David Dingli, MD PhD, Ronald S. Go, MD, Amie Fonder, PA-C, MS, Yi L. Hwa, APRN, CNP, DNP, Miriam A. Hobbs, APRN, CNP, DNP, Wilson I Gonsalves, MD, Dania Kaehlyn Helgeson, Taxiarchis Kourelis, MD, Betsy Laplant, MS, Stephen J Russell, MD PhD, Eli Muchtar, MD, Rahma M Warsame, MD, S. Vincent Rajkumar, MD, Robert A. Kyle, MD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1905.
https://doi.org/10.1182/blood-2019-132035
Published: 2019
Journal Articles

Romiplostim Improves Platelet Recovery after UCB Transplant

Free
Georgios E. Christakopoulos, MD, Todd E. DeFor, MS, Stefanie M Hage, RN, John E. Wagner, MD, Michael A. Linden, MD PhD, Claudio G Brunstein, MD PhD, Nelli Bejanyan, MD, Michael R Verneris, MD, Angela R. Smith, MD MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 1979.
https://doi.org/10.1182/blood-2019-125424
Published: 2019
Journal Articles

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

Free
Elisabet E. Manasanch, MD, Sundar Jagannath, MD, Hans C. Lee, MD, Krina K. Patel, MDMSc, Connor Graham, BA, Gregory P. Kaufman, MD, Sheeba K. Thomas, MD, Swami Iyer, Sham Mailankody, MBBS, Neha Korde, MD, Behrang Amini, MD PhD, Pei Lin, MDDM,MDC, Zuzana Berkova, PhD, Donna M. Weber, MD, Feng Lei, MS, Nikoletta Lendvai, MD PhD, Michelle Hildebrandt, PhD, Sattva S Neelapu, MD, Robert Z. Orlowski, MD, PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3116.
https://doi.org/10.1182/blood-2019-123205
Published: 2019
Journal Articles

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Free
Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Shien Guo, PhD, Weiqin Liao, MS, Carrie Brownstein, MD, Ruben A Mesa, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2207.
https://doi.org/10.1182/blood-2019-129386
Published: 2019
Journal Articles

Effect of Depression on Health Related Quality of Life and Adherence and Its Correlation with Response Rates in Patients of Chronic Myeloid Leukemia on First Line Imatinib and Nilotinib - a Prospective, Institutional Analysis of Real World Data from India

Free
Pratibha Bhatia, MSc, BSc, Sumeet Prakash Mirgh, MBBS,MDDM, Vishvdeep Khushoo, MBBS,MDDM, Faran Naim, MD DNB, Ambar Garg, MD DNB, Rayaz Ahmed, MDDM, Narendra Agrawal, MD DM, Dinesh Bhurani, MD DM, FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 3500.
https://doi.org/10.1182/blood-2019-131763
Published: 2019